EHS
EHS

CAR T Rx Kymriah Gains Expanded Approval for Some Large B-Cell Lymphomas

The FDA has granted tisagenlecleucel (Kymriah, Novartis) its second indication—the treatment of adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy. The approval includes treatment of DLBCL as well as high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma, but it does not include primary central nervous system lymphoma.
EHS
Back to top button